EU panel backs approval of pomalidomide for multiple myeloma

Celgene International's oral pomalidomide has been recommended for approval against multiple myeloma by the European Medicines Agency's Committee for Medicinal Products for Human Use. The panel concluded that the drug's benefits are greater than its risks in people who have been given at least two previous treatments including both lenalidomide and bortezomib. The drug was approved in the U.S. this year with the brand name Pomalyst.

View Full Article in:

Medscape (free registration) · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA